Article Information
History
- October 21, 2022.
Article Versions
- Version 1 (August 9, 2021 - 08:05).
- Version 2 (August 9, 2021 - 14:19).
- Version 3 (October 29, 2021 - 07:26).
- You are viewing Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Lavanya Visvabharathy1,*,¶,
- Barbara A. Hanson1,
- Zachary S. Orban1,
- Patrick H. Lim1,
- Nicole M. Palacio2,
- Millenia Jimenez1,
- Jeffrey R. Clark1,
- Edith L. Graham1,
- Eric M. Liotta1,
- George Tachas, Director3,
- Pablo Penaloza-MacMaster2 and
- Igor J. Koralnik1,*
- 1Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago IL 60611 USA
- 2Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago IL 60611 USA
- 3Drug Discovery & Patents, Antisense Therapeutics Ltd., Melbourne, Australia
- ↵*Corresponding authors: Igor J. Koralnik, M.D.: igor.koralnik{at}northwestern.edu; Lavanya Visvabharathy, Ph.D: lavanya.visvabharathy{at}northwestern.edu